Osteoarthritis Clinical Trial Findings

Osteoarthritis is a degenerative disease that effects the elderly through inflammation in the joint. In young patient, the anabolic and catabolic process in the joint were regulated by a plethora of factors. However, old age may lead to the dysregulation of this balance, and osteoarthritis typically emerge as the result of cytokine storm that cause inflammation in the joint. 

MSCs is known to be able to regulate inflammation via secretion of various cytokines that the suppresses inflammation. Accordingly, Stempeutics had venture into the osteoarthritic indication of Stempeucel^®. To date, phase I study in India, and phase II studies in India and Malaysia, demonstrated the efficacy of Stempeucel^® to alleviate pain and symptoms related to osteoarthritis. As a result, Stempeucel^® has received marketing approval by the Drugs Controller General of India (DCGI) for osteoarthritis indication.